In fact IL-6 can be produced by both androgen sensitive than the insensitive prostate cancer cells, for example under TLR4 activation from LPS binding and up-regulation of both ligand and its receptor are overexpressed in prostate cancer cells (called, as example, LNCaP and DU145 cell lines) but also in a disease that precede the development of prostate adenocarcinoma called high-grade prostatic intraepithelial neoplasia (PIN). Here, IL6 is linked to prostate carcinoma.